Quick tip: You don't need to wait for a cure to act. If you have a family history of genetic heart disease, ask your doctor about genetic testing and clinical trial eligibility now — the CRISPR pipeline is moving faster than most people realize.
For the roughly 1 in 500 people living with hypertrophic cardiomyopathy and the 1 in 250 with familial hypercholesterolemia, the promise of CRISPR isn't abstract science fiction. It's deeply personal.
CRISPR-Cas9 — the gene-editing tool that allows scientists to make precise cuts to DNA — has already cured sickle cell disease in approved therapies. Now, researchers are setting their sights on the heart.
Here's what you need to know about the latest breakthroughs, the hurdles that remain, and what this means for patients over the next five years.
Researchers at the University of Pennsylvania used CRISPR to edit the PCSK9 gene in monkeys — a gene that regulates cholesterol. The result? LDL cholesterol dropped by up to 60% and remained low for months. PCSK9 is already a proven drug target, with statins and PCSK9 inhibitors on the market, but a one-time genetic edit could replace daily pills altogether.
Key takeaway: A single CRISPR treatment targeting PCSK9 could potentially replace lifelong cholesterol medication.
Harvard Medical School researchers employed a newer technique called base editing — which changes a single DNA letter without cutting the double helix — to treat familial hypercholesterolemia in mice. Cholesterol levels dropped by 50%, and the approach produced fewer off-target effects than traditional CRISPR.
The first systemic CRISPR therapy in humans (NTLA-2001) targeted the TTR gene in the liver, which produces a toxic protein that damages the heart and nerves. After a single infusion, the trial reduced the disease-causing protein by 90%. Because this condition leads to heart failure, the cardiac connection is direct and significant.
Researchers at Oregon Health & Science University corrected the mutation responsible for hypertrophic cardiomyopathy in human embryos. The embryos were not implanted — this was purely proof-of-concept — but it demonstrated that inherited heart disease could theoretically be eliminated before birth.
The liver is an easy target for CRISPR because it filters blood and readily absorbs lipid nanoparticles. The heart, however, is far more difficult. Researchers are exploring viral vectors and direct injection, but getting enough editing machinery into cardiac muscle remains a major hurdle.
CRISPR can sometimes edit the wrong part of the genome. Base editing reduces this risk, but it doesn't eliminate it. For a preventive therapy intended for otherwise healthy people, the safety bar is extremely high — and rightly so.
Editing embryos raises profound ethical questions. Most countries restrict or ban germline editing, and the scientific consensus is that it's not ready for clinical use — even if the technical challenges were solved.
Current status: No CRISPR therapy for heart disease is approved. The 2022 trial for transthyretin amyloidosis (NCT04601051) is ongoing but not yet complete.
Timeline: The first human trial specifically targeting PCSK9 for heart disease is expected to begin by 2025. If successful, a therapy could reach the market in 5–10 years.
Cost: Gene therapies are expensive — Casgevy, the approved sickle cell treatment, costs over $2 million per patient. Early access will likely be limited to severe cases.
Key takeaway: CRISPR for heart disease is promising but not yet a cure. The realistic timeline for patient access is 5–10 years, and cost will be a major barrier.
Not yet. It has shown promise in animal models and early trials, but no CRISPR therapy for heart disease is approved. The most advanced work targets conditions that affect the heart indirectly, like transthyretin amyloidosis and high cholesterol.
Delivery to heart tissue is difficult, off-target edits remain a safety concern, and germline editing raises significant ethical issues that have slowed progress.
No. The first CRISPR therapy for any condition (sickle cell disease) was approved in 2023. The first human trial for heart disease is expected to begin by 2025.
If trials succeed, expect 5–10 years before approval. Cost will likely be a major barrier, with therapies potentially priced in the millions.
Stay updated on the latest CRISPR heart disease research by subscribing to our newsletter and sharing this article with someone who might benefit.